Abstract
Cross-sex hormone therapy is increasingly accepted as essential to the wellbeing of transgender individuals. Cross-sex hormones have been shown to alter clinical laboratory values, but separate reference ranges have not been established for transgender patients due to a lack of knowledge and data on this population. Healthcare providers often rely on the results of laboratory tests to make diagnoses and treatment plans, and it is imperative that they do not misinterpret these results in transgender patients. The goal of this study is to investigate how changes in laboratory values in female-to-male (FTM) transgender patients are related to duration of testosterone treatment. We conducted a retrospective chart review of FTM patients attending transgender-specific clinics at an urban county hospital (Parkland, Dallas, TX) and a community clinic (Dallas Resource Center). Patients were included if they were biologic females taking testosterone, between the ages of 18 and 80, and had laboratory test results from at least one month after initiation of testosterone treatment. Each patient's complete blood count, metabolic panel, liver function tests, lipid panel, and hormone levels were recorded with a median follow-up time of 12 months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
